Serina Therapeutics (SER)
Serina Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as pharmaceutical preparations.
44K
Short interest
settlement 2026-10-15
1.1
Days to cover
+0.1 days vs prior
55.6%
Short share of volume
2026-11-02
729
Fails to deliver
settlement 2026-10-14
Thu 12 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in SER is 43,870 shares, down 75,490 shares over the last month. Over the last 48 readings it ranged from 24,615 shares (30 April 2025) to 1,005,090 shares (30 January 2026). The latest reading sits at the bottom of that range. At the reported average volume of 38K shares a day that is 1.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/ser" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 43,870 | -22.5% | 38,492 | 1.14 |
| 2026-09-30 | 56,600 | -52.6% | 121,092 | 1.00 |
| 2026-09-15 | 119,360 | +70.3% | 82,864 | 1.44 |
| 2026-08-31 | 70,094 | -51.8% | 53,172 | 1.32 |
| 2026-08-14 | 145,548 | -34.7% | 69,205 | 2.10 |
| 2026-07-31 | 222,920 | -21.7% | 26,087 | 8.55 |
| 2026-07-15 | 284,546 | -0.3% | 54,394 | 5.23 |
| 2026-06-30 | 285,430 | -25.7% | 82,559 | 3.46 |
| 2026-06-15 | 383,983 | +11.3% | 182,466 | 2.10 |
| 2026-05-29 | 345,042 | +6.8% | 91,974 | 3.75 |
| 2026-05-15 | 323,055 | +9.9% | 79,414 | 4.07 |
| 2026-04-30 | 293,855 | -21.4% | 72,379 | 4.06 |
| 2026-04-15 | 373,657 | -21.8% | 237,848 | 1.57 |
| 2026-03-31 | 478,077 | +332.6% | 16,536,923 | 1.00 |
| 2026-03-13 | 110,517 | -15.1% | 54,587 | 2.02 |
| 2026-02-27 | 130,122 | +41.9% | 96,117 | 1.35 |
| 2026-02-13 | 91,712 | -90.9% | 348,643 | 1.00 |
| 2026-01-30 | 1,005,090 | +1079.9% | 7,588,539 | 1.00 |
| 2026-01-15 | 85,186 | +223.0% | 165,456 | 1.00 |
| 2025-12-31 | 26,375 | -27.5% | 31,603 | 1.00 |
| 2025-12-15 | 36,399 | -14.5% | 15,509 | 2.35 |
| 2025-11-28 | 42,561 | -32.9% | 13,627 | 3.12 |
| 2025-11-14 | 63,378 | +19.1% | 25,110 | 2.52 |
| 2025-10-31 | 53,221 | -23.2% | 29,109 | 1.83 |
| 2025-10-15 | 69,282 | +18.3% | 49,688 | 1.39 |
| 2025-09-30 | 58,557 | -28.6% | 24,893 | 2.35 |
| 2025-09-15 | 82,003 | -61.8% | 51,228 | 1.60 |
| 2025-08-29 | 214,808 | +467.9% | 624,559 | 1.00 |
| 2025-08-15 | 37,826 | -26.3% | 11,871 | 3.19 |
| 2025-07-31 | 51,313 | +32.3% | 36,249 | 1.42 |
| 2025-07-15 | 38,775 | +19.8% | 31,074 | 1.25 |
| 2025-06-30 | 32,356 | +12.1% | 13,289 | 2.43 |
| 2025-06-13 | 28,877 | -1.2% | 19,733 | 1.46 |
| 2025-05-30 | 29,240 | -0.7% | 16,525 | 1.77 |
| 2025-05-15 | 29,438 | +19.6% | 2,817 | 10.45 |
| 2025-04-30 | 24,615 | -1.9% | 12,536 | 1.96 |
| 2025-04-15 | 25,087 | -17.4% | 14,890 | 1.68 |
| 2025-03-31 | 30,359 | -2.9% | 12,690 | 2.39 |
| 2025-03-14 | 31,255 | +0.5% | 7,603 | 4.11 |
| 2025-02-28 | 31,112 | -8.9% | 7,227 | 4.30 |
| 2025-02-14 | 34,152 | +16.2% | 13,394 | 2.55 |
| 2025-01-31 | 29,381 | -7.8% | 14,961 | 1.96 |
| 2025-01-15 | 31,850 | +6.5% | 22,808 | 1.40 |
| 2024-12-31 | 29,898 | -16.8% | 40,309 | 1.00 |
| 2024-12-13 | 35,937 | +14.0% | 51,112 | 1.00 |
| 2024-11-29 | 31,521 | -1.5% | 12,059 | 2.61 |
| 2024-11-15 | 31,998 | +25.2% | 19,306 | 1.66 |
| 2024-10-31 | 25,549 | -11.4% | 15,335 | 1.67 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of SER volume is 55.6%, down 20.1 points over the last five sessions. Over the last 30 readings it ranged from 3.7% (7 October 2026) to 75.7% (26 October 2026). The latest reading is 19.5 points above the 30-session average of 36.2%, on 13K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 7K | 13K | 55.6% | 2,869 |
| 2026-10-30 | 56K | 91K | 61.5% | 3,506 |
| 2026-10-29 | 12K | 21K | 59.2% | 1,503 |
| 2026-10-28 | 3K | 17K | 15.0% | 143 |
| 2026-10-27 | 11K | 58K | 18.3% | 1,227 |
| 2026-10-26 | 18K | 24K | 75.7% | 0 |
| 2026-10-23 | 554 | 2K | 29.4% | 0 |
| 2026-10-22 | 13K | 22K | 60.4% | 0 |
| 2026-10-21 | 12K | 32K | 38.3% | 0 |
| 2026-10-20 | 10K | 28K | 37.3% | 327 |
| 2026-10-19 | 4K | 11K | 35.9% | 3,083 |
| 2026-10-16 | 2K | 3K | 46.5% | 0 |
| 2026-10-15 | 12K | 20K | 57.6% | 8 |
| 2026-10-14 | 5K | 25K | 21.3% | 0 |
| 2026-10-13 | 3K | 9K | 35.0% | 0 |
| 2026-10-12 | 15K | 50K | 29.4% | 0 |
| 2026-10-09 | 839 | 8K | 10.3% | 0 |
| 2026-10-08 | 430 | 2K | 23.0% | 0 |
| 2026-10-07 | 151 | 4K | 3.7% | 0 |
| 2026-10-06 | 191 | 3K | 6.4% | 0 |
| 2026-10-05 | 5K | 13K | 36.1% | 0 |
| 2026-10-02 | 4K | 6K | 59.0% | 0 |
| 2026-10-01 | 11K | 25K | 44.5% | 0 |
| 2026-09-30 | 479 | 5K | 10.2% | 0 |
| 2026-09-29 | 7K | 10K | 66.3% | 0 |
| 2026-09-28 | 2K | 6K | 25.7% | 0 |
| 2026-09-25 | 9K | 19K | 46.2% | 0 |
| 2026-09-24 | 10K | 48K | 21.7% | 0 |
| 2026-09-23 | 1K | 3K | 29.5% | 0 |
| 2026-09-22 | 4K | 17K | 25.7% | 670 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in SER is 729 shares, down 19,751 shares over the last settlement date. Over the last 30 readings it ranged from 10 shares (24 September 2026) to 829,377 shares (29 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 729 | $1.82 | $1K |
| 2026-10-13 | 20,480 | $1.94 | $40K |
| 2026-10-08 | 543 | $2.01 | $1K |
| 2026-10-05 | 55 | $1.96 | $108 |
| 2026-10-01 | 67 | $2.00 | $134 |
| 2026-09-29 | 829,377 | $2.01 | $1.7M |
| 2026-09-24 | 10 | $2.19 | $22 |
| 2026-09-22 | 1,105 | $2.31 | $3K |
| 2026-09-21 | 1,476 | $2.25 | $3K |
| 2026-09-18 | 643 | $2.22 | $1K |
| 2026-09-14 | 67 | $2.22 | $149 |
| 2026-09-11 | 1,549 | $2.50 | $4K |
| 2026-09-10 | 4,640 | $2.57 | $12K |
| 2026-09-09 | 1,303 | $2.50 | $3K |
| 2026-09-08 | 711 | $2.73 | $2K |
| 2026-09-04 | 796 | $2.69 | $2K |
| 2026-09-03 | 792 | $2.62 | $2K |
| 2026-08-31 | 191 | $2.46 | $470 |
| 2026-08-28 | 91 | $2.52 | $229 |
| 2026-08-27 | 286 | $2.63 | $752 |
| 2026-08-26 | 91 | $2.70 | $246 |
| 2026-08-25 | 16,142 | $2.63 | $42K |
| 2026-08-24 | 94 | $2.87 | $270 |
| 2026-08-21 | 548 | $2.65 | $1K |
| 2026-08-20 | 336 | $2.72 | $914 |
| 2026-08-19 | 22,886 | $2.62 | $60K |
| 2026-08-18 | 8,965 | $2.85 | $26K |
| 2026-08-17 | 17,956 | $2.80 | $50K |
| 2026-08-14 | 8,663 | $2.85 | $25K |
| 2026-08-12 | 3,633 | $2.78 | $10K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for SER in the last 90 days. The most recent filings are listed below. Latest filing: Brannan Stephen K. (Director) on 2026-07-07.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-07-07 | Brannan Stephen K. | Director | Buy | 1K | $2.03 | $2K | 1K |
| 2026-06-17 | Venkatesan Jay | Director | Conversion | 224K | $2.25 | $504K | 232K |
| 2026-06-17 | Bailey Gregory | Director | Conversion | 6.7M | $2.25 | $15.0M | 8.6M |
| 2026-06-17 | Bailey Gregory | Director | Conversion | 1.8M | $2.25 | $4.0M | 1.9M |
| 2026-06-12 | WILSON KAREN J | Director | Buy | 5K | $1.77 | $9K | 10K |
| 2026-06-11 | WILSON KAREN J | Director | Buy | 5K | $1.75 | $9K | 5K |
| 2026-05-26 | LEDGER STEVEN A | Chief Executive Officer | Grant | 10K | $1.93 | $19K | 10K |
| 2026-05-22 | Venkatesan Jay | Director | Buy | 589 | $1.78 | $1K | 589 |
| 2026-05-22 | WILSON KAREN J | Director | Buy | 10K | $1.93 | $19K | 20K |
| 2026-05-21 | WILSON KAREN J | Director | Buy | 10K | $1.77 | $18K | 10K |
| 2026-05-19 | Marshall Richard Peter | Director | Buy | 12K | $1.65 | $20K | 12K |
| 2026-03-31 | Venkatesan Jay | Director | Grant | 8K | $1.94 | $15K | 8K |
| 2026-03-31 | Bailey Gregory | Director | Grant | 60K | $1.94 | $116K | 127K |
| 2026-03-23 | Moreadith Randall | Chief Scientific Officer | Sell | 7K | $2.86 | $19K | 0 |
| 2026-03-23 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 7K | $0.06 | $390 | 7K |
| 2026-03-19 | Moreadith Randall | Chief Scientific Officer | Sell | 39K | $2.50 | $98K | 0 |
| 2026-03-19 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 39K | $0.06 | $2K | 39K |
| 2026-02-02 | Moreadith Randall | Chief Scientific Officer | Sell | 7K | $3.03 | $20K | 0 |
| 2026-02-02 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 7K | $0.06 | $390 | 7K |
| 2026-01-28 | Moreadith Randall | Chief Scientific Officer | Sell | 7K | $3.57 | $23K | 0 |
| 2026-01-28 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 7K | $0.06 | $390 | 7K |
| 2026-01-22 | Moreadith Randall | Chief Scientific Officer | Sell | 3K | $2.95 | $7K | 0 |
| 2026-01-22 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 3K | $0.06 | $150 | 3K |
| 2026-01-21 | Moreadith Randall | Chief Scientific Officer | Sell | 2K | $3.00 | $6K | 0 |
| 2026-01-21 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 2K | $0.06 | $120 | 2K |
| 2026-01-20 | Moreadith Randall | Chief Scientific Officer | Sell | 2K | $3.07 | $6K | 0 |
| 2026-01-20 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 2K | $0.06 | $120 | 2K |
| 2026-01-14 | Moreadith Randall | Chief Scientific Officer | Sell | 1K | $2.50 | $3K | 0 |
| 2026-01-14 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 1K | $0.06 | $65 | 1K |
| 2026-01-13 | Moreadith Randall | Chief Scientific Officer | Sell | 5K | $2.50 | $14K | 0 |
| 2026-01-13 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 5K | $0.06 | $325 | 5K |
| 2026-01-08 | Moreadith Randall | Chief Scientific Officer | Sell | 13K | $2.69 | $35K | 0 |
| 2026-01-08 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 13K | $0.06 | $780 | 13K |
| 2025-12-23 | Moreadith Randall | Chief Scientific Officer | Sell | 4K | $2.60 | $11K | 0 |
| 2025-12-23 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 4K | $0.06 | $246 | 4K |
| 2025-12-22 | Moreadith Randall | Chief Scientific Officer | Sell | 6K | $2.67 | $15K | 0 |
| 2025-12-22 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 6K | $0.06 | $340 | 6K |
| 2025-12-16 | Moreadith Randall | Chief Scientific Officer | Sell | 3K | $2.96 | $10K | 0 |
| 2025-12-16 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 3K | $0.06 | $194 | 3K |
| 2025-12-12 | Moreadith Randall | Chief Scientific Officer | Sell | 2K | $3.26 | $6K | 0 |
| 2025-12-12 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 2K | $0.06 | $102 | 2K |
| 2025-12-11 | Moreadith Randall | Chief Scientific Officer | Sell | 4K | $3.24 | $12K | 0 |
| 2025-12-11 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 4K | $0.06 | $213 | 4K |
| 2025-12-10 | Moreadith Randall | Chief Scientific Officer | Sell | 645 | $3.35 | $2K | 0 |
| 2025-12-10 | Moreadith Randall | Chief Scientific Officer | Grant | 645 | $0.06 | $39 | 645 |
| 2025-12-09 | Moreadith Randall | Chief Scientific Officer | Sell | 600 | $3.31 | $2K | 0 |
| 2025-12-09 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 600 | $0.06 | $36 | 600 |
| 2025-12-03 | Moreadith Randall | Chief Scientific Officer | Sell | 5K | $3.52 | $18K | 0 |
| 2025-12-03 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 5K | $0.06 | $300 | 5K |
| 2025-12-02 | Moreadith Randall | Chief Scientific Officer | Sell | 2K | $3.91 | $6K | 0 |
| 2025-12-02 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 2K | $0.06 | $90 | 2K |
| 2025-11-25 | Moreadith Randall | Chief Scientific Officer | Sell | 6K | $3.90 | $23K | 6K |
| 2025-11-25 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 6K | $0.06 | $358 | 12K |
| 2025-11-24 | Moreadith Randall | Chief Scientific Officer | Sell | 535 | $3.94 | $2K | 0 |
| 2025-11-24 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 535 | $0.06 | $32 | 535 |
| 2025-11-18 | Moreadith Randall | Chief Scientific Officer | Sell | 7K | $3.75 | $24K | 0 |
| 2025-11-18 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 7K | $0.06 | $390 | 7K |
| 2025-11-10 | Moreadith Randall | Chief Scientific Officer | Sell | 7K | $4.10 | $27K | 0 |
| 2025-11-10 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 7K | $0.06 | $390 | 7K |
| 2025-11-05 | Moreadith Randall | Chief Scientific Officer | Sell | 3K | $4.24 | $14K | 0 |
| 2025-11-05 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 3K | $0.06 | $204 | 3K |
| 2025-11-04 | Moreadith Randall | Chief Scientific Officer | Sell | 3K | $4.40 | $14K | 0 |
| 2025-11-04 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 3K | $0.06 | $186 | 3K |
| 2025-10-28 | Moreadith Randall | Chief Scientific Officer | Sell | 6K | $4.96 | $28K | 0 |
| 2025-10-28 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 6K | $0.06 | $333 | 6K |
| 2025-10-27 | Moreadith Randall | Chief Scientific Officer | Sell | 949 | $5.19 | $5K | 0 |
| 2025-10-27 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 949 | $0.06 | $57 | 949 |
| 2025-10-20 | Moreadith Randall | Chief Scientific Officer | Sell | 7K | $4.97 | $32K | 0 |
| 2025-10-20 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 7K | $0.06 | $390 | 7K |
| 2025-10-13 | Moreadith Randall | Chief Scientific Officer | Sell | 4K | $5.20 | $22K | 0 |
| 2025-10-13 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 4K | $0.06 | $260 | 4K |
| 2025-08-26 | Moreadith Randall | Chief Scientific Officer | Sell | 46K | $7.01 | $320K | 0 |
| 2025-08-26 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 46K | $0.06 | $3K | 46K |
| 2025-08-25 | Moreadith Randall | Chief Scientific Officer | Sell | 2K | $5.65 | $12K | 0 |
| 2025-08-25 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 2K | $0.06 | $123 | 2K |
| 2025-08-20 | Moreadith Randall | Chief Scientific Officer | Sell | 2K | $5.10 | $11K | 0 |
| 2025-08-20 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 2K | $0.06 | $125 | 2K |
| 2025-08-18 | Moreadith Randall | Chief Scientific Officer | Sell | 2K | $5.25 | $12K | 0 |
| 2025-08-18 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 2K | $0.06 | $134 | 2K |
| 2025-08-12 | Moreadith Randall | Chief Scientific Officer | Sell | 6K | $5.25 | $29K | 0 |
| 2025-08-12 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 6K | $0.06 | $330 | 6K |
| 2025-08-04 | Moreadith Randall | Chief Scientific Officer | Sell | 6K | $5.17 | $28K | 0 |
| 2025-08-04 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 6K | $0.06 | $330 | 6K |
| 2025-07-29 | Moreadith Randall | Chief Scientific Officer | Sell | 4K | $6.50 | $27K | 0 |
| 2025-07-29 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 4K | $0.06 | $252 | 4K |
| 2025-07-28 | Moreadith Randall | Chief Scientific Officer | Sell | 7K | $5.89 | $38K | 0 |
| 2025-07-28 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 7K | $0.06 | $390 | 7K |
| 2025-07-21 | Moreadith Randall | Chief Scientific Officer | Sell | 7K | $5.34 | $35K | 0 |
| 2025-07-21 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 7K | $0.06 | $390 | 7K |
| 2025-07-14 | Moreadith Randall | Chief Scientific Officer | Sell | 7K | $5.01 | $33K | 0 |
| 2025-07-14 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 7K | $0.06 | $390 | 7K |
| 2025-07-07 | Moreadith Randall | Chief Scientific Officer | Sell | 7K | $5.67 | $37K | 0 |
| 2025-07-07 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 7K | $0.06 | $390 | 7K |
| 2025-06-30 | Moreadith Randall | Chief Scientific Officer | Sell | 7K | $5.78 | $38K | 0 |
| 2025-06-30 | Moreadith Randall | Chief Scientific Officer | Exercise or conversion | 7K | $0.06 | $390 | 7K |
| 2025-03-28 | LEDGER STEVEN A | Chief Executive Officer | Other transaction | 96K | $0.00 | $0 | 96K |
| 2025-01-31 | Juvenescence Ltd | TenPercentOwner | Grant | 500K | $10.00 | $5.0M | 3.3M |
| 2024-12-17 | Bailey Gregory | Director | Buy | 4K | $4.59 | $18K | 67K |
| 2024-11-27 | Juvenescence Ltd | TenPercentOwner | Grant | 500K | $10.00 | $5.0M | 2.8M |
| 2024-09-20 | Bailey Gregory | Director | Buy | 1K | $6.03 | $7K | 63K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON2 Form 144 notices on file for SER worth $810K at the prices reported; 0 in the last 90 days worth $0. Latest: Moreadith Randall filed on 2026-01-20 to sell 91,000 shares ($279K) from 2026-01-20.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-01-20 | Moreadith RandallOfficer | 91K | $279K | 0.853% | 2026-01-20 | Stifel Nicolaus & Company Inc |
| 2025-10-14 | Moreadith RandallOfficer | 89K | $530K | 0.867% | 2025-10-13 | Stifel Nicolaus & Company Inc |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON3 holders report 5% or more of SER in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is Juvenescence Limited at 27.3% of the class (4,400,781 shares), filed 2026-07-22 for an event on 2026-03-20.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-07-22 | 13D/Ano. 37 | Juvenescence Limitedcorporation | 4.4M | 27.3% | 2026-03-20 |
| 2026-07-22 | 13D/Ano. 37 | JuvVentures (UK) Limitedcorporation | 4.4M | 27.3% | 2026-03-20 |
| 2026-05-04 | 13G | Sio Capital Management, LLCinvestment adviser | 1.0M | 6.7% | 2026-03-31 |
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Serina Therapeutics reported revenue of $0, down 100.0% from the same quarter a year earlier, and net loss of $6.4M (-0.55 diluted EPS). In FY 2025 it generated -$18.0M of operating cash flow.
- Cash
- $23.0M
- Total assets
- $25.8M
- Shares outstanding
- 25,400,473
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $0 | -$6.4M | n/a | -0.55 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$6.9M | n/a | -0.58 |
| Q4 FY 2025derived | 2025-12-31 | $0 | -$3.3M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $0 | -$4.6M | n/a | -0.45 |
| Q2 FY 2025 | 2025-06-30 | $130K | -$6.4M | -4960.0% | -0.66 |
| Q1 FY 2025 | 2025-03-31 | $0 | -$4.8M | n/a | -0.49 |
| Q4 FY 2024derived | 2024-12-31 | -$14K | -$2.7M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $14K | $1.4M | 10071.4% | 0.13 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $130K | -$19.2M | -$18.0M | $59K | n/a | n/a |
| FY 2024 | 2024-12-31 | $56K | -$11.1M | -$17.1M | $22K | n/a | n/a |
| FY 2023 | 2023-12-31 | $3.2M | $5.3M | -$2.5M | n/a | n/a | n/a |
| FY 2022 | 2022-12-31 | $34K | -$10.5M | -$5.9M | n/a | n/a | n/a |
| FY 2021 | 2021-12-31 | $144K | -$8.7M | -$7.9M | n/a | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-10 from the cover page.
What this page is
Serina Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Serina Therapeutics (SER), SEC CIK 1708599, listed on NYSE, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-01-20.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-07-22.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-13.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-07-07.JSON and CSV
- Company record
- EDGAR filing index for CIK 1708599Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of SER is sold short?
43,870 shares were held short at the 2026-10-15 settlement, 1.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is SER's daily short volume?
On 2026-11-02, 7,035 of the 12,648 SER shares reported to FINRA were sold short, 55.6% of the day's reported volume. Short volume is a flow for one day, not a position.
Does SER have fails to deliver?
The SEC's latest file shows 729 SER shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are SER insiders buying or selling?
No open-market insider trades were reported for SER in the last 90 days. The most recent filings are listed below. Latest filing: Brannan Stephen K. (Director) on 2026-07-07.
Have SER insiders filed to sell?
2 Form 144 notices on file for SER worth $810K at the prices reported; 0 in the last 90 days worth $0. Latest: Moreadith Randall filed on 2026-01-20 to sell 91,000 shares ($279K) from 2026-01-20.
Who owns 5% or more of SER?
3 holders report 5% or more of SER in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is Juvenescence Limited at 27.3% of the class (4,400,781 shares), filed 2026-07-22 for an event on 2026-03-20.
What did SER report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Serina Therapeutics reported revenue of $0, down 100.0% from the same quarter a year earlier, and net loss of $6.4M (-0.55 diluted EPS). In FY 2025 it generated -$18.0M of operating cash flow.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.